Clinical Policy: Eteplirsen (Exondys 51)
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PHAR.288 alerts
Get alerted when Policy MDN.CP.PHAR.288 changes without checking for updates manually.
Monitor payer policy activity
Defines Meridian Medicaid medical necessity and prior authorization criteria for eteplirsen (Exondys 51) for treatment of Duchenne muscular dystrophy patients with mutations amenable to exon 51 skipping; applies to providers seeking coverage under the payer's Medicaid line of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Eteplirsen (Exondys 51)
Initial Therapy
Covered when ALL of the following are met for initial therapy:
All requirements must be documented
Continuation Therapy
Covered when ALL of the following are met for continuation:
Approval duration: 6 months
Not Authorized Indications
Not authorized unless off-label criteria are satisfied
Coverage is not authorized for non–FDA approved indications unless the request includes sufficient documentation of efficacy and safety in accordance with the payer’s off‑label use policies (see CP.PMN.53 for Medicaid) or other applicable evidence of coverage documents.
Initial Therapy
Initial Therapy
Initial therapy coverage requires all criteria be met:
Approval duration: 6 months; documentation of all items required
Continuation Therapy
Continued Therapy
Criteria for continued coverage (must meet all):
Approval duration: 6 months
Coding and Clinical Thresholds
| J1428 | Injection, eteplirsen, 10 mg |
Provider Actions and Requirements
Prior authorization required for Exondys 51 (J1428)
Prior authorization is required for Exondys 51 (J1428: injection, eteplirsen, 10 mg); requests reviewed under this policy require submission of documentation to demonstrate that approval criteria are met.
- Use HCPCS code J1428 when submitting claims or prior authorization requests.
Concurrent corticosteroid use and prior corticosteroid trial required
Exondys 51 must be prescribed concurrently with an oral corticosteroid (e.g., prednisone, deflazacort [Emflaza], or vamorolone [Agamree]) unless contraindicated; in addition, an inadequate response despite adherent use of an oral corticosteroid for ≥ 6 months is required prior to approval unless contraindicated or intolerant.
- Concurrent corticosteroid prescription is required for both initial and continued therapy unless contraindications or clinically significant adverse effects exist.
- Documentation should show adherent corticosteroid use for ≥ 6 months or a documented contraindication/intolerance.
Submit supporting clinical documentation with requests
Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria.
- Include recent assessments required by the criteria (e.g., 6MWT, LVEF, FVC) within specified timeframes.
- Provide evidence of neurologist involvement and history of corticosteroid use or documented contraindication/intolerance.
Incomplete documentation may lead to denial and medical director review
Requests may be denied if submitted documentation does not support that the member meets all approval criteria; all requests reviewed under this policy may require medical director review.
- Ensure documentation demonstrates genetic confirmation of a mutation amenable to exon 51 skipping and required baseline or follow-up measurements.
- Be prepared for potential medical director review when clinical information is incomplete or unclear.
Step Therapy Requirements
| Step | Requirement | Duration / Notes |
|---|---|---|
| {"text":"1","status":""},{"text":"Trial of oral corticosteroid therapy (examples: prednisone, deflazacort [Emflaza], or vamorolone [Agamree])","status":""},{"text":">= 6 months of adherent use unless contraindicated or intolerant; inadequate response evidenced by significant decline in 6MWT, LVEF, or FVC","status":""} |
Background
Eteplirsen (Exondys 51) is an antisense oligonucleotide therapy designed to induce exon 51 skipping in the DMD gene to promote production of dystrophin. It is indicated under accelerated approval for treatment of Duchenne muscular dystrophy in patients with a confirmed mutation amenable to exon 51 skipping; continued approval may require confirmatory studies.
Corticosteroids are considered standard of care in DMD and are recommended by guideline groups; Exondys 51 is intended to be used in the context of corticosteroid therapy unless contraindicated.
Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.